^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    P30-EPS

    i
    Other names: P30-EPS
    Associations

    News

    Trials
    Company:
    Duke University, National Cancer Institute
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    1year
    ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM (clinicaltrials.gov)
    P1, N=36, Recruiting, Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MGMT (6-O-methylguanine-DNA methyltransferase) • BIRC5 (Baculoviral IAP repeat containing 5)
    |
    IDH wild-type
    |
    Hiltonol (poly-ICLC) • P30-EPS
    almost2years
    ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Initiation date: Nov 2022 --> Feb 2023
    Trial initiation date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase) • BIRC5 (Baculoviral IAP repeat containing 5)
    |
    IDH wild-type
    |
    Hiltonol (poly-ICLC) • P30-EPS
    2years
    ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Initiation date: Jul 2022 --> Nov 2022
    Trial initiation date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase) • BIRC5 (Baculoviral IAP repeat containing 5)
    |
    IDH wild-type
    |
    Hiltonol (poly-ICLC) • P30-EPS